G Gilead Sciences
| Market Cap | $173.41B |
| P/E Ratio | 20.61 |
| Forward P/E | 14.52 |
| Dividend Yield | 2.35% |
| Beta | 0.40 |
| 52W Range | $94.40 - $154.92 |
| # Hedge Funds | 3 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Hedge Fund Ownership
| Investor 3 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox | 1.74% | $3.23B | 26,283,511 | Reduce 12.78% |
| Charles Bobrinskoy Ariel Investments | 0.27% | $25.17M | 205,052 | Reduce 6.27% |
| Mairs & Power Growth Fund Mairs & Power Inc | 0.00% | $279.00K | 2,275 | — |
Insider Trading
| Insider Name of the company insider who made the trade 40 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| O'Day Daniel PatrickChairman & CEO | Sale | 10,000 | $136.82 | $1.37M | 27 Mar 2026 | 30 Mar 2026 |
| Dickinson Andrew DChief Financial Officer | Sale | 3,000 | $144.23 | $432.69K | 16 Mar 2026 | 16 Mar 2026 |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | 3,000 | $144.23 | $432.69K | 16 Mar 2026 | 16 Mar 2026 |
| O'Day Daniel PatrickChairman & CEO | Sale | 100 | $145.71 | $14.57K | 27 Feb 2026 | 02 Mar 2026 |
| O'Day Daniel PatrickChairman & CEO | Sale | 6,419 | $145.18 | $931.90K | 27 Feb 2026 | 02 Mar 2026 |
| O'Day Daniel PatrickChairman & CEO | Sale | 3,481 | $144.04 | $501.39K | 27 Feb 2026 | 02 Mar 2026 |
| Dickinson Andrew DChief Financial Officer | Sale | 3,000 | $154.43 | $463.29K | 17 Feb 2026 | 18 Feb 2026 |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | 200 | $155.62 | $31.12K | 17 Feb 2026 | 18 Feb 2026 |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | 9,395 | $154.91 | $1.46M | 17 Feb 2026 | 18 Feb 2026 |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | 18,405 | $154.18 | $2.84M | 17 Feb 2026 | 18 Feb 2026 |
| O'Day Daniel PatrickChairman & CEO | Sale | 115,640 | $150.00 | $17.35M | 05 Feb 2026 | 06 Feb 2026 |
| O'Day Daniel PatrickChairman & CEO | Sale | 5,032 | $139.54 | $702.19K | 28 Jan 2026 | 29 Jan 2026 |
| O'Day Daniel PatrickChairman & CEO | Sale | 4,968 | $140.24 | $696.73K | 28 Jan 2026 | 29 Jan 2026 |
| O'Day Daniel PatrickChairman & CEO | Sale | 115,640 | $135.00 | $15.61M | 23 Jan 2026 | 26 Jan 2026 |
| Bluestone Jeffrey | Sale | 5,000 | $123.50 | $617.50K | 20 Jan 2026 | 21 Jan 2026 |
| Mercier JohannaChief Commercial Officer | Sale | 3,000 | $124.31 | $372.93K | 15 Jan 2026 | 16 Jan 2026 |
| Dickinson Andrew DChief Financial Officer | Sale | 3,000 | $124.31 | $372.93K | 15 Jan 2026 | 16 Jan 2026 |
| O'Day Daniel PatrickChairman & CEO | Sale | 10,000 | $124.83 | $1.25M | 29 Dec 2025 | 30 Dec 2025 |
| Dickinson Andrew DChief Financial Officer | Sale | 3,000 | $122.00 | $366.00K | 15 Dec 2025 | 16 Dec 2025 |
| Mercier JohannaChief Commercial Officer | Sale | 3,000 | $122.00 | $366.00K | 15 Dec 2025 | 16 Dec 2025 |
| Kramer Kelly A. | Sale | 2,805 | $127.10 | $356.52K | 28 Nov 2025 | 01 Dec 2025 |
| Bluestone Jeffrey | Sale | 5,000 | $125.08 | $625.40K | 28 Nov 2025 | 01 Dec 2025 |
| O'Day Daniel PatrickChairman & CEO | Sale | 3,212 | $125.91 | $404.43K | 28 Nov 2025 | 01 Dec 2025 |
| Kelly A. KramerDirector | Sale | 2,805 | $127.10 | $356.52K | 28 Nov 2025 | 01 Dec 2025 |
| Jeffrey BluestoneDirector | Sale | 5,000 | $125.08 | $625.40K | 28 Nov 2025 | 01 Dec 2025 |
| O'Day Daniel PatrickChairman & CEO | Sale | 6,788 | $126.84 | $861.02K | 28 Nov 2025 | 01 Dec 2025 |
| Kramer Kelly A. | Sale | 2,806 | $127.11 | $356.67K | 26 Nov 2025 | 01 Dec 2025 |
| Kelly A. KramerDirector | Sale | 2,806 | $127.11 | $356.67K | 26 Nov 2025 | 01 Dec 2025 |
| Mercier JohannaChief Commercial Officer | Sale | 25,524 | $125.83 | $3.21M | 17 Nov 2025 | 18 Nov 2025 |
| Dickinson Andrew DChief Financial Officer | Sale | 2,500 | $125.23 | $313.07K | 17 Nov 2025 | 18 Nov 2025 |
| Mercier JohannaChief Commercial Officer | Sale | 2,476 | $126.26 | $312.61K | 17 Nov 2025 | 18 Nov 2025 |
| Telman Deborah HEVP, Corporate Affairs & GC | Sale | 500 | $122.90 | $61.45K | 12 Nov 2025 | 13 Nov 2025 |
| Telman Deborah HEVP, Corporate Affairs & GC | Sale | 35,965 | $122.30 | $4.40M | 12 Nov 2025 | 13 Nov 2025 |
| Telman Deborah HEVP, Corporate Affairs & GC | Sale | 17,181 | $124.00 | $2.13M | 12 Nov 2025 | 13 Nov 2025 |
| O'Day Daniel PatrickChairman & CEO | Sale | 7,978 | $119.54 | $953.67K | 28 Oct 2025 | 29 Oct 2025 |
| O'Day Daniel PatrickChairman & CEO | Sale | 2,022 | $118.82 | $240.26K | 28 Oct 2025 | 29 Oct 2025 |
| Mercier JohannaChief Commercial Officer | Sale | 3,000 | $118.08 | $354.24K | 15 Oct 2025 | 16 Oct 2025 |
| Dickinson Andrew DChief Financial Officer | Sale | 2,500 | $118.08 | $295.20K | 15 Oct 2025 | 16 Oct 2025 |
| Johanna MercierChief Commercial Officer | Sale | 3,000 | $118.08 | $354.24K | 15 Oct 2025 | 16 Oct 2025 |
| Andrew D DickinsonChief Financial Officer | Sale | 2,500 | $118.08 | $295.20K | 15 Oct 2025 | 16 Oct 2025 |
Frequently Asked Questions
What is GILD stock price today?
Gilead Sciences (GILD) is currently trading at $139.71. The stock has a 52-week range of $94.40 to $154.92 and a market capitalization of $173.41B.
Is GILD a good stock to buy in 2026?
Gilead Sciences has a P/E ratio of 20.6 (forward P/E: 14.5), a dividend yield of 2.35%, and 1-year performance of +27.6%. 3 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling GILD stock?
There have been 40 insider transactions for GILD in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has GILD stock performed over the past year?
Gilead Sciences (GILD) has returned +27.6% over the past 12 months. The stock traded between $94.40 and $154.92 during this period, and is currently at $139.71.
Which hedge funds own GILD (Gilead Sciences)?
3 tracked hedge funds currently hold GILD in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is GILD's market cap and valuation?
Gilead Sciences (GILD) has a market capitalization of $173.41B. The trailing P/E ratio is 20.6 and forward P/E is 14.5. The stock is classified in the Healthcare sector.
What is GILD's revenue and profitability?
Gilead Sciences reported revenue of $29.44B with net income of $8.51B and a profit margin of 0.29%. The stock has a beta of 0.40.
What sector is GILD in and who are its biggest institutional holders?
Gilead Sciences (GILD) operates in the Healthcare sector. It is held by 3 tracked hedge funds. See the ownership table above for the complete list.